IP Library › Granted Patent US 8,501,771

Granted Patent B2

US 8,501,771 · App. 12/191,697 · Granted Aug 6, 2013

Aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,501,771
App. No.: 12/191,697
Granted: Aug 6, 2013
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention relates to aminoalcohol-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one aminoalcohol-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the aminoalcohol-substituted aryldihydroisoquinolinones of the invention and their derivatives as MCH antagonists.

Claims (403)

1. A compound of formula (I)

wherein:

D is N or C(R1″);

R1, R1′, R1″ and R1′″ are

independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R3)(R4), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), N(R7)CO(R8), N(R9)SO 2 (R10), CO(R11), or (C(R12)(R13)) x -O(R14);

R3, R4, R5, R6, R7 and R9 are

independently of one another H or (C 1 -C 8 )-alkyl,

R3 and R4, or R5 and R6

independently of one another, taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R8, R10 and R11 are

independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R12 and R13 are

independently of one another H, or (C 1 -C 8 )-alkyl;

R14 is H, (C 1 -C 6 )-alkyl, or aryl;

x is 0 , 1, 2, 3, 4, 5 or 6;

R2 is H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R15)(R16), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R17)(R18), N(R19)CO(R20), N(R21)SO 2 (R22), CO(R23), or (C(R24)(R25)) x′ -O(R26);

R15, R16, R17, R18, R19 and R21 are

independently of one another H, or (C 1 -C 8 )-alkyl,

R15 and R16, or R17 and R18

independently of one another, taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R20, R22 and R23 are

independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R24 and R25 are

independently of one another H, or (C 1 -C 8 )-alkyl;

R26 is H, (C 1 -C 6 )-alkyl, or aryl;

x′ is 0, 1, 2, 3, 4, 5 or 6;

Y is C(R27)(R27′)C(R28)(R28′), or C(R29)=C(R29′);

R27, R27′, R28, R28′, R29 and R29′ are

independently of one another H, or (C 1 -C 8 )-alkyl;

X is C(R30)=C(R30′);

R30 and R30′ are

independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R15)(R16), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R17)(R18), N(R19)CO(R20), N(R21)SO 2 (R22), CO(R23), or (C(R24)(R25)) x′ -O(R26);

A is a linker having 2 to 8 members, where the members are selected from the group consisting of O, S, CO, C(R32)(R33), C(R34)=C(R34′), cyclopropylene, resulting in a chemically reasonable radical;

R34 and R34′ are

independently of one another H or (C 1 -C 8 )-alkyl;

R32 and R33 are

independently of one another H, (C 1 -C 6 )OH, or O—(C 1 -C 6 )-alkyl;

B is (C 1 -C 4 )-alkoxy-(C 1 -C 4 )alkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl-(C-C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C-C 4 )-alkyl, oxo, CO(R37), CON(R38)(R39), hydroxy, COO(R40), N(R41)CO(C 1 -C 6 )-alkyl, N(R42)(R43), SO 2 CH 3 ;

R37, R38, R39, R40, R41, R42 and R43

independently of one another H or (C 1 -C 8 )-alkyl,

R38 and R39, or R42 and R43

independently of one another taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

L is a bond or (C1-C3)-alkylene;

Q is N(R53′)(R54′), or a bi-, tri- or spirocyclic saturated or partly unsaturated ring structure having one nitrogen atom and 0-3 additional heteroatoms selected from the group consisting of N, O and S, where the rings of the structure may be spiro-linked, fused or bridged, and where the ring system is optionally substituted one or more times by F, OH, CF 3 , CN, OCF 3 , oxo, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, CO(R44), (C(R45)(R46)) o -R47, or CO(C(R45)(R46)) p -R48;

R44 is H, (C 1 -C 8 )-alkyl;

R45 and R46 are

independently of one another H, (C 1 -C 8 )-alkyl OH, (C 3 -C 8 )-cycloalkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

o and p are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R47 and R48 are

independently of one another OH, F, O—(C 1 -C 8 )-alkyl, CON(R49)(R50), N(R51)CO(R52), N(R53)(R54), CO 2 (R55), SO 2 Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which is optionally substituted one or more times by F, Cl, Br, CF 3 , (C 1 -C 8 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, CO(R56), oxo, or OH;

R49, R50, R51, R52, R55 and R56 are

independently of one another H or (C 1 -C 8 )-alkyl,

R49 and R50

taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R53, R54, R53′ and R54′ are

independently of one another H, (C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, CO(R57), (C(R58)(R59)) q -R60, CO(C(R61)(R62)) r -R63, or CO—(CH 2 ) o′ -O—(C 1 -C 6 )-alkyl,

R53 and R54, or R53′ and R54′

taken together with the nitrogen atom to which they are bonded form a 4 to 10-membered mono-, bi- or spirocyclic ring which optionally comprises 1 to 3 additional heteroatoms selected from the group consisting of N, O and S, and which is optionally substituted one or more times by F, Cl, Br, CF 3 , O—(C-C 8 )-alkyl, (C 1 -C 6 )-alkyl, CO(R64), oxo, OH, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, CON(R65)(R66), N(R67)CO(R68), N(R69)(R70), CO 2 (R71), or SO 2 (C 1 -C 6 )-alkyl;

o′ is 0, 1, 2, 3, 4, 5 or 6;

R58 and R59 are

independently of one another H, (C 1 -C 6 )-alkyl, or OH;

R57, R61, R62, R64, R65, R66, R67, R68, R69, R70 and R71

independently of one another H, or (C 1 -C 6 )-alkyl,

R69 and R70

taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R60 and R63 are

independently of one another OH, F, O—(C 1 -C 6 )-alkyl, CN, COO(R78), N(R74)CO(C 1 -C 6 )-alkyl, N(R76)(R77), CON(R72)(R73), SO 2 (C 1 -C 6 )-alkyl, or a 3-12 membered mono-, bi- or spirocyclic ring which optionally comprises one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring is optionally substituted by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 C 6)-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, O—(C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, N(R76)(R77), COO(R78), SO 2 (C 1 -C 6 )-alkyl or COOH; and

R72, R73, R74, R76, R77 and R78 are

independently of one another H, or (C 1 -C 8 )-alkyl,

R72 and R73, or R76 and R77

independently of one another taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom from the group of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

provided that when L is (C 1 -C 3 )-alkylene, then B is not an aromatic radical, a cycloalkyl radical, an alk-2-en-1-yl radical or a cycloalk-2-en-1-yl radical, and A does not contain the moiety C(R34′)C(R34′);

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein

B is (C 1 -C 4 )alkoxy-(C 1 -C 4 )-alkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic nonaromatic ring which optionally comprises 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R37), CON(R38)(R39), hydroxy, COO(R40), N(R41)CO(C 1 -C 6 )-alkyl, N(R42)(R43), or SO 2 CH 3 ;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , wherein

B is (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic nonaromatic ring which optionally comprises 0 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R37), CON(R38)(R39), hydroxy, COO(R40), N(R41)CO(C 1 -C 6 )-alkyl, N(R42)(R43) or SO 2 CH 3 ;

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , wherein

B is (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, or a 3 to 10-membered mono-, bi- or spirocyclic nonaromatic ring which optionally comprises 0 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 - C 4 )-alkyl,oxo, CO(R37), hydroxy, COO(R40), N(R41)CO(C 1 -C 6 )-alkyl, N(R42)(R43) or SO 2 CH 3 ;

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 , wherein

B is (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, or a 3 to 10-membered mono-, bi- or spirocyclic nonaromatic ring which optionally comprises 0 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, CF 3 , (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R37), hydroxy, N(R41)CO(C 1 -C 6 )-alkyl or SO 2 CH 3 ;

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 , wherein

Q is N(R53′)(R54′) or a group selected from

wherein the group is optionally substituted one or more times by F, OH, oxo, (C 1 -C 8 )-alkyl, O—(C 1 -C 8 )-alkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

R53′ is H, (C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, CO—(C 1 -C 8 )-alkyl, CO—(CH 2 ) o′ —O—(C 1 -C 6 )-alkyl, or CO(C(R61)(R62)) r N(R76)(R77),

R54′ is (C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, or (C 3 -C 8 )-alkynyl;

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 4 to 10-membered mono-, bi- or spirocyclic ring which optionally comprises 1 to 3 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system is optionally substituted by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), CON(R65)(R66), hydroxy, COO(R71), N(R67)CO(C 1 -C 6 )-alkyl, N(R69)(R70) or SO 2 (C 1 -C 6 )-alkyl;

o′ is 0, 1, 2, 3, 4, 5 or 6; and

q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6;

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 , wherein

Q is N(R53′)(R54′) or a group selected from:

wherein the group is optionally substituted one or more times by F, OH, oxo, (C 1 -C 8 )-alkyl, O—(C 1 -C 8 )-alkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 , wherein Q is:

or a pharmaceutically acceptable salt thereof

9. The compound according to claim 1 , wherein

R53′ is (C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, CO—(C 1 -C 8 )-alkyl, CO—(CH 2 ) o ′—O—(C 1 -C 6 )-alkyl, or CO(C(R61)(R62)) r N(R76)(R77),

R54′ is (C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, or (C 3 -C 8 )-alkynyl,

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 4 to 10-membered mono-, bi- or spirocyclic ring which optionally comprises 0 to 3 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system is optionally substituted by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), CON(R65)(R66), hydroxy, COO(R71), N(R67)CO(C 1 -C 6 )-alkyl, N(R69)(R70) or SO 2 (C 1 -C 6 )-alkyl;

o′ is 0, 1, 2, 3, 4, 5 or 6; and

q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6;

or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1 , wherein

R53′ and R54′independently of one another are (C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl,

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 4 to 10-membered mono-, bi- or spirocyclic ring which optionally comprises 1 to 2 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system is optionally substituted by F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), hydroxy, N(R67)CO(C 1 -C 6 )-alkyl, or SO 2 (C 1 -C 6 )-alkyl; and

R60 is OH, F, O—(C 1 -C 6 )-alkyl, N(R74)CO(C 1 -C 6 )-alkyl, SO 2 (C 1 -C 6 )-alkyl, or a 3-12 membered mono-, bi- or spirocyclic ring which optionally comprises one or more heteroatoms from the group consisting of N, O and S, and the 3-12 membered ring is optionally substituted by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R76)(R77) or SO 2 (C 1 -C 6 )-alkyl;

or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 , wherein

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 4 to 7-membered monocyclic ring which optionally comprises 1 to 2 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system is optionally substituted by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), CON(R65)(R66), hydroxy, COO(R71), N(R67)CO(C 1 -C 6 )-alkyl, N(R69)(R70) or SO 2 (C 1 -C 6 )-alkyl;

or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1 , wherein

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 6 to 10-membered bi- or spirocyclic ring which optionally comprises 1 to 3 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system is optionally substituted by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), CON(R65)(R66), hydroxy, COO(R71), N(R67)CO(C 1 -C 6 )-alkyl, N(R69)(R70) or SO 2 (C 1 -C 6 )-alkyl;

or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1 , wherein

or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 , wherein

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 6 to 10-membered bi- or spirocyclic non aromatic ring selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1 , wherein

O-L-Q is

R53′ is (C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, CO—(C 1 -C 8 )-alkyl, CO—(CH 2 ) o′ —O—(C 1 -C 6 )-alkyl, or CO(C(R61)(R62)) r N(R76)(R77),

R54′ is (C(R58)(R59)) q -R60,(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, or (C 3 -C 8 )-alkynyl,

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 6 to 10-membered bi- or spirocyclic nonaromatic ring which optionally comprises 1 to 3 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system is optionally substituted by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), CON(R65)(R66), hydroxy, COO(R71), N(R67)CO(C 1 -C 6 )-alkyl, N(R69)(R70) or SO 2 (C 1 -C 6 )-alkyl;

or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 1 , wherein O-L-Q is:

each of which is optionally substituted one or more times by F, OH, oxo, (C 1 -C 8 )-alkyl, O—(C 1 -C 8 )-alkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl; and

R53′ is (C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, CO—(C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, CO(C(R61)(R62)) r -N(R76)(R77), or CO—(CH 2 ) o′ —O—(C 1 -C 6 )-alkyl;

or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 1 , wherein O-L-Q is:

which is optionally substituted one or more times by F, OH, oxo, (C 1 -C 8 )-alkyl, O—(C 1 -C 8 )-alkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl; and

or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 1 , wherein

X is C(R30)=C(R30′);

Y is C(R29)=C(R29′);

O-L-Q is

R53′ is (C 1 -C 8 )-alkyl, (C(R58)(R59)) q -R60, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, CO—(C 1 -C 8 )-alkyl, CO—(CH 2 ) o′ —O—(C 1 -C 6 )-alkyl, or CO(C(R61)(R62)) r N(R76)(R77),

R54′ is (C(R58)(R59)) q -R60, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, or (C 3 -C 8 )-alkynyl, or

R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 6 to 10-membered bi- or spirocyclic nonaromatic ring which optionally comprises 1 to 3 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system is optionally substituted by F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), CON(R65)(R66), hydroxy, COO(R71), N(R67)CO(C 1 -C 6 )-alkyl, N(R69)(R70) or SO 2 (C 1 -C 6 )-alkyl;

R60 is OH, F, O—(C 1 -C 6 )-alkyl, N(R74)CO(C 1 -C 6 )-alkyl, or 3-12 membered mono-, bi- or spirocyclic nonaromatic ring which optionally comprises one or more heteroatoms from the group consisting of N, O and S, and the 3-12 membered ring is optionally substituted by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R76)(R77) or SO 2 (C 1 -C 6 )-alkyl;

or a pharmaceutically acceptable salt thereof.

19. A compound of formula (I)

wherein

D is N or C(R1″);

R1, R1′, Rl″ and R1″′ are independently of one another H, F, Cl, Br, I, OH, CF 3 ,NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R3)(R4), SO 2 -CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), N(R7)CO(R8), N(R9)SO 2 (R10), CO(R11), or (C(R12)(R13)) x -O(R14);

R3, R4, R5, R6, R7 and R9 are independently of one another H or (C 1 -C 8 )-alkyl,

R3 and R4, or R5 and R6 independently of one another, taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R8, R10 and R11 are independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R12 and R13 are independently of one another H, or (C 1 -C 8 )-alkyl;

R14 is H, (C 1 -C 6 )-alkyl, or aryl;

x is 0, 1, 2, 3, 4, 5 or 6;

R15, R16, R17, R18, R19 and R21 are independently of one another H, or (C 1 -C 8 )-alkyl,

R15 and R16, or R17 and R18 independently of one another, taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R20, R22 and R23 are independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R24 and R25 are independently of one another H, or (C 1 -C 8 )-alkyl;

R26 is H, (C 1 -C 6 )-alkyl, or aryl;

x′ is 0, 1, 2, 3, 4, 5 or 6;

Y is C(R27)(R27′)C(R28)(R28′);

R27, R27′, R28, R28′are independently of one another H, or (C 1 -C 8 )-alkyl;

X is C(R30)=C(R30′);

R30 and R30′ are independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R15)(R16), SO 2 -CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R17)(R18), N(R19)CO(R20), N(R21)SO 2 (R22), CO(R23), or (C(R24)(R25)) x′ -O(R26);

A is a bond or a linker having 1 to 8 members, where the members are selected from the group consisting of O, S, SO 2 , N(R31), CO, C(R32)(R33), C(R34)=C(R34′), cyclopropylene, and C≡C, resulting in a chemically reasonable radical;

R31, R34 and R34′ are independently of one another H or (C 1 -C 8 )-alkyl;

R32 and R33 are independently of one another H, (C 1 -C 6 )-alkyl, OH, or O—(C 1 -C 6 )-alkyl;

B is H, N(R35)(R36), hydroxy-(C 1 -C 4 )-alkyl, (C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 C 4 )alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R37), CON(R38)(R39), hydroxy, COO(R40), N(R41)CO(C 1 -C 6 )-alkyl, N(R42)(R43), SO 2 CH 3 , SCF 3 or S—(C 1 -C 6 )-alkyl;

R35, R36, R37, R38, R39, R40, R41, R42 and R43 independently of one another H or (C 1 -C 8 )-alkyl,

R38 and R39, or R42 and R43 independently of one another taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

L is a bond or (C1-C3)-alkylene;

R44 is H, (C 1 -C 8 )-alkyl;

R45 and R46 are independently of one another H, (C 1 -C 8 )-alkyl, OH, (C 3 -C 8 )-cycloalkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

o and p are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R47 and R48 are independently of one another OH, F, O—(C 1 -C 8 )-alkyl, CON(R49)(R50), N(R51)CO(R52), N(R53)(R54), CO 2 (R55), SO 2 Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which is optionally substituted one or more times by F, Cl, Br, CF 3 , (C 1 -C 8 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, CO(R56), oxo, or OH;

R49, R50, R51, R52, R55 and R56 are independently of one another H or (C 1 -C 8 )-alkyl,

R49 and R50 taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group consisting of NH, N—(C 1 -C)-alkyl, oxygen and sulfur;

R53, R54, R53′ and R54′ are independently of one another H, (C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 )-alkenyl, (C 3 -C 8 )-alkynyl, CO(R57), (C(R58)(R59)) q -R60, CO(C(R61)(R62)) r -R63, or CO—(CH 2 ) o′ —O—(C 1 -C 6 )-alkyl,

R53 and R54, or R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 4 to 10-membered mono-, bi- or spirocyclic ring which optionally comprises 1 to 3 additional heteroatoms selected from the group consisting of N, O and S, and which is optionally substituted one or more times by F, Cl, Br, CF 3 , O—(C 1 -C 8 )-alkyl, (C 1 -C 6 )-alkyl, CO(R64), oxo, OH, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, CON(R65)(R66), N(R67)CO(R68), N(R69)(R70), CO,(R71), or SO 2 (C 1 -C 6 )-alkyl;

o′ is 0, 1, 2, 3, 4, 5 or 6;

R58 and R59 are independently of one another H, (C 1 -C 6 )-alkyl, or OH;

R57, R61, R62, R64, R65, R66, R67, R68, R69, R70 and R71

independently of one another H, or (C 1 -C 6 )-alkyl,

R69 and R70 taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R60 and R63 are independently of one another OH, F, O—(C 1 -C 6 )-alkyl, COO(R78), N(R74)CO(C 1 -C 6 )-alkyl, N(R76)(R77), CON(R72)(R73), SO 2 (C 1 -C 6 )-alkyl, or a 3-12 membered mono-, bi- or spirocyclic ring which optionally comprises one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring is optionally substituted by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, O—(C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, N(R76)(R77), COO(R78), SO 2 (C 1 -C 6 )-alkyl or COOH; and

R72, R73, R74, R76, R77 and R78 are independently of one another H, or (C 1 -C 8 )-alkyl,

R72 and R73, or R76 and R77 independently of one another taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom from the group of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 1 , wherein

Y is C(R29)=C(R29′); and

R29 and R29′ are H;

or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 1 , wherein

R30 and R30′ are

independently from another H, F, Cl, O—(C 1 -C 6 )-Alkyl, or (C 1 -C 6 )-Alkyl;

or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 1 , wherein

R27, R27′, R28, R28′, R29, R29′, R30 and R30′ are H;

or a pharmaceutically acceptable salt thereof.

23. The compound according to claim 1 , wherein

R2 is H;

or a pharmaceutically acceptable salt thereof

24. The compound according to claim 1 , which is a compound of formula (Ia)

or a pharmaceutically acceptable salt thereof.

25. A compound of formula (I)

wherein

D is N or C(R1″);

R1, R1′, R1″ and R1″′ are independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R3)(R4), SO 2 -CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), N(R7)CO(R8), N(R9)SO 2 (R10), CO(R11), or (C(R12)(R13)) x -O(R14);

R3, R4, R5, R6, R7 and R9 are independently of one another H or (C 1 -C 8 )-alkyl,

R3 and R4, or R5 and R6 independently of one another, taken together with the nitrogen atom to which the are bonded form a 5-6 membered ring which optionally comprises one additional heteroatom selected from the group consisting of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur;

R8, R10 and R11 are independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R12 and R13 are independently of one another H, or (C 1 -C 8 )-alkyl;

R14 is H, (C 1 -C 6 )-alkyl, or aryl;

x is 0, 1, 2, 3, 4, 5 or 6;

R15, R16, R17, R18, R19 and R21 are independently of one another H, or (C 1 -C 8 )-alkyl,

R20, R22 and R23 are independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R24 and R25 are independently of one another H, or (C 1 -C 8 )-alkyl;

R26 is H, (C 1 -C 6 )-alkyl, or aryl;

x′ is 0, 1, 2, 3, 4, 5 or 6;

Y is C(R27)(R27′)C(R28)(R28′), or C(R29)=C(R29′);

R27, R27′, R28, R28′, R29 and R29′ are independently of one another H, or (C 1 -C 8 )-alkyl;

X is C(R30)=C(R30′);

R30 and R30′ are independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R15)(R16), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R17)(R18), N(R19)CO(R20), N(R21)SO 2 (R22), CO(R23), or (C(R24)(R25)) x′ -O(R26);

B-A is

wherein the tetrahydrofuranyl ring is optionally substituted once by methyl or OH;

L is a bond or (C1-C3)-alkylene;

R44 is H, (C 1 -C 8 )-alkyl;

R45 and R46 are independently of one another H, (C 1 -C 8 )-alkyl, OH, (C 3 -C 8 )-cycloalkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

o and p are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R49, R50, R51, R52, R55 and R56 are independently of one another H or (C 1 -C 8 )-alkyl,

o′ is 0, 1, 2, 3, 4, 5 or 6;

R58 and R59 are independently of one another H, (C 1 -C 6 )-alkyl, or OH;

R57, R61, R62, R64, R65, R66, R67, R68, R69, R70 and R71 independently of one another H, or (C 1 -C 6 )-alkyl,

q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R60 and R63 are independently of one another OH, F, O—(C 1 -C 6 )-alkyl, CN, COO(R78), N(R74)CO(C 1 -C 6 )-alkyl, N(R76)(R77), CON(R72)(R73), SO 2 (C 1 -C 6 )-alkyl, or a 3-12 membered mono-, bi- or spirocyclic ring which optionally comprises one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring is optionally substituted by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, O—(C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, N(R76)(R77), COO(R78), SO 2 (C 1 -C 6 )-alkyl or COOH; and

R72, R73, R74, R76, R77 and R78 are independently of one another H, or (C 1 -C 8 )-alkyl,

or a phafinaceutically acceptable salt thereof.

26. The compound according to claim 1 , wherein B-A is

or a pharmaceutically acceptable salt thereof.

27. The compound according to claim 1 , wherein

A is CH 2 —O, CH 2 CH 2 O, COCH 2 O, O—CO—CH 2 —O, CH 2 CH 2 CH 2 O, or COCH 2 CH 2 O;

or a pharmaceutically acceptable salt thereof.

28. The compound according to claim 1 , wherein

B is (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, or a monocyclic ring selected from the group consisting of

where the monocyclic ring is optionally substituted once or twice by F, CF 3 , CN, methyl, ethyl, methoxy, oxo, hydroxy, or SO 2 -methyl;

or a pharmaceutically acceptable salt thereof.

29. A compound of formula (Ib)

wherein:

D is N or C(R1″);

R1, R1′, R1″ and R1″′ are independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R3)(R4), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), N(R7)CO(R8), N(R9)SO 2 (R10), CO(R11), or (C(R12)(R13)) x -O(R14);

R3, R4, R5, R6, R7 and R9 are independently of one another H or (C 1 -C 8 )-alkyl,

R8, R10 and R11 are independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R12 and R13 are independently of one another H, or (C 1 -C 8 )-alkyl;

R14 is H, (C 1 -C 6 )-alkyl, or aryl;

x is 0, 1, 2, 3, 4, 5 or 6;

R2 is H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 -alkylene-aryl, S-aryl, N(R15)(R16), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R17)(R18), N(R19)CO(R20), N(R21)SO 2 (R22), CO(R23), or (C(R24)(R25)) x′ -O(R26);

R15, R16, R17, R18, R19 and R21 are independently of one another H, or (C 1 -C 8 )-alkyl,

R20, R22 and R23 are independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R24 and R25 are independently of one another H, or (C 1 -C 8 )-alkyl;

R26 is H, (C 1 -C 6 )-alkyl, or aryl;

x′ is 0, 1, 2, 3, 4, 5 or 6;

Y is C(R27)(R27′)C(R28)(R28′), or C(R29)=C(R29′);

R27, R27′, R28, R28′, R29 and R29′ are independently of one another H, or (C 1 -C 8 )-alkyl;

X is C(R30)=C(R30′);

R30 and R30′ are independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R15)(R16), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R17)(R18), N(R19)CO(R20), NCR21)SO 2 (R22), CO(R23), or (C(R24)(R25)) x′ -O(R26);

A′ is a bond or a linker having 1 to 5 members, where the members are selected from the group consisting of O, N(R31), CO, and (C(R32)R(R33)), resulting in a chemically reasonable radical;

R31 is H or (C 1 -C 8 )-alkyl;

R32 and R33 are independently of one another H, (C 1 -C 6 )-alkyl, OH, or O—(C 1 -C 6 )-alkyl;

B is H, N(R35)(R36), hydroxy-(C 1 -C 4 )-alkyl, (C 1 -C 8 )- alkyl , (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R37), CON(R38)(R39), hydroxy, COO(R40), N(R41)CO(C 1 -C 6 )-alkyl, N(R42)(R43), SO 2 CH 3 , SCF 3 or S—(C 1 -C 6 )-alkyl;

R35, R36, R37, R38, R39, R40, R41, R42 and R43 independently of one another H or (C 1 -C 8 )-alkyl,

L is a bond or (C1-C3)-alkylene;

Q is N(R53′)(R54′), or a bi-, tri- or spirocyclic saturated or partly unsaturated ring structure having one nitrogen atom and 0-3 additional heteroatoms selected from the group consisting of N, O and S, where the rings of the structure may be spiro-linked, fused or bridged, and where the ring system is optionally substituted one or more times by F, OH, CF 3 , CN, OCF 3 , oxo, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, (CO(R44), (C(R45)(R46)) o -R47, or CO(C(R45)(R46)) p -R48;

R44 is H, (C 1 -C 8 )-alkyl;

R45 and R46 are independently of one another H, (C 1 -C 8 )-alkyl, OH, (C 3 -C 8 )-cycloalkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

o and p are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R49, R50, R51, R52, R55 and R56 are independently of one another H or (C 1 -C 8 )-alkyl,

o′ is 0, 1, 2, 3, 4, 5 or 6;

R58 and R59 are independently of one another H, (C 1 -C 6 )-alkyl, or OH;

R57, R61, R62, R64, R65, R66, R67, R68, R69, R70 and R71 independently of one another H, or (C 1 -C 6 )-alkyl,

q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R72, R73, R74, R76, R77 and R78 are independently of one another H, or (C 1 -C 8 )-alkyl,

or a pharmaceutically acceptable salt thereof.

30. The compound according to claim 1 , wherein

A is a linker having 2 to 4 members, where the members are selected from the group consisting of O, CO, and C(R32)(R33) resulting in a chemically reasonable radical, provided that the linker has no CO—O or O—CO groups;

or a pharmaceutically acceptable salt thereof.

31. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier.

32. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and at least one additional active ingredient which has beneficial effect on metabolic disturbance or a disorder associated therewith.

33. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and at least one antidiabetic active ingredient.

34. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and at least one lipid modulator.

35. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and at least one antiobesity active ingredient.

36. The compound according to claim 1 , wherein of formula (I)

D is N or C(R1″);

R1, R1′, R1′ and R1″′ are independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R3)(R4), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), N(R7)CO(R8), N(R9)SO 2 (R10), CO(R11), or (C(R12)(R13)) x -O(R14);

R3, R4, R5, R6, R7 and R9 are independently of one another H or (C 1 -C 8 )-alkyl,

R8, R10 and R11 are independently of one another H, (C 1 -C 8 -alkyl, or aryl;

R12 and R13 are independently of one another H, or (C 1 -C 8 )-alkyl;

R14 is H, (C 1 -C 6 )-alkyl, or aryl;

x is 0, 1, 2, 3, 4, 5 or 6;

R15, R16, R17, R18, R19 and R21 are independently of one another H, or (C 1 -C 8 )-alkyl,

R20, R22 and R23 are independently of one another H, (C 1 -C 8 )-alkyl, or aryl;

R24 and R25 are independently of one another H, or (C 1 -C 8 )-alkyl;

R26 is H, (C 1 -C 6 )-alkyl, or aryl;

x′ is 0, 1, 2, 3, 4, 5 or 6;

Y is C(R29)=C(R29′);

R27, R27′, R28, R28′, R29 and R29′ are independently of one another H, or (C 1 -C 8 )-alkyl;

X is C(R30)=C(R30′);

R30 and R30′ are independently of one another H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, N(R15)(R16), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R17)(R18), N(R19)CO(R20), N(R21)SO 2 (R22), CO(R23), or (C(R24)(R25)) x′ -O(R26);

A is C(R34)=C(R34′);

R34 and R34′ are independently of one another H or (C 1 -C 8 )-alkyl;

B is a 3 to 10-membered mono-, bi-, tri- or spirocyclic non-aromatic ring which may comprise 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system is optionally substituted one or more times by F, Cl, Br, CF 3 , NO 2 , CN, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R37), CON(R38)(R39), hydroxy, COO(R40), N(R41)CO(C 1 -C 6 )-alkyl, N(R42)(R43), SO 2 CH 3 , SCF 3 or S—(C 1 -C 6 )-alkyl;

R37, R38, R39, R40, R41, R42 and R43 independently of one another H or (C 1 -C 8 )-alkyl,

L is a bond or (C1-C3)-alkylene;

R44 is H, (C 1 -C 8 )-alkyl;

R45 and R46 are independently of one another H, (C 1 -C 8 )-alkyl, OH, (C 3 -C 8 )-cycloalkyl, or (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl;

o and p are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R49, R50, R51, R52, R55 and R56 are independently of one another H or (C 1 -C 8 )-alkyl,

R53 and R54, or R53′ and R54′ taken together with the nitrogen atom to which they are bonded form a 4 to 10-membered mono-, bi- or spirocyclic ring which optionally comprises 1 to 3 additional heteroatoms selected from the group consisting of N, O and S, and which is optionally substituted one or more times by F, Cl, Br, CF 3 , O—(C 1 -C 8 )alkyl, (C 1 -C 6 )-alkyl, CO(R64), oxo, OH, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, CON(R65)(R66), N(R67)CO(R68), N(R69)(R70), CO 2 (R71), or SO 2 (C 1 -C 6 )-alkyl;

o′ is 0, 1, 2, 3, 4, 5 or 6;

R58 and R59 are independently of one another H, (C 1 -C 6 )-alkyl, or OH;

R57, R61, R62, R64, R65, R66, R67, R68, R69, R70 and R71

independently of one another H, or (C 1 -C 6 )-alkyl,

q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6;

R72, R73, R74, R76, R77 and R78 are independently of one another H, or (C 1 -C 8 )-alkyl,

or a pharmaceutically acceptable salt thereof.

Assignments (2)

CHANGE OF NAME Recorded Jun 20, 2012

From: SANOFI-AVENTIS

To: SANOFI

Reel/Frame 028413/0927 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2008

From: SCHWINK, LOTHAR; STENGELIN, SIEGFRIED; GOSSEL, MATTHIAS; HESSLER, GERHARD; HAACK, TORSTEN; LENNIG, PETRA

To: SANOFI-AVENTIS

Reel/Frame 021945/0480 →